The role of crude saliva and purified salivary mucins in the inhibition of the Human Immunodeficiency Virus type 1

Virology Journal

Anwar S Mall³  Paul Roux¹  Corena de Beer²  Zoe Lotz³  Julia Peacocke³ 

[1] Department of Paediatric Medicine, University of Cape Town, Observatory, Cape, 7925, South Africa;Discipline of Medical Virology, University of Stellenbosch and National Health Laboratory Service, Tygerberg, South Africa;Department of Surgery, Division of General Surgery, University of Cape Town, Observatory, Cape, 7925, South Africa

关键词: Inhibition assay;    HIV-1;    MUC7;    MUC5B;    Mucin;   

Others  :  1154002
DOI  :  10.1186/1743-422X-9-177

 received in 2011-09-12, accepted in 2012-08-06,  发布年份 2012

【 摘 要 】

Background

Sub-Saharan Africa is the world’s worst HIV-AIDS affected region. More interventions to manage this pandemic are urgently required. Transmission of the virus through an exchange of saliva is rarely known to occur. This project sought to verify statistically previous findings in our laboratory, that crude saliva from uninfected individuals together with its purified mucin components inhibited HIV-1, whilst mucins from infected saliva did not show this inhibition, in an in vitro assay.

Methods

Saliva was extracted in 4 M guanidinium hydrochloride and proteolytic inhibitors at pH 6.5, followed by the isolation of MUC5B and MUC7 by Sepharose 4B gel filtration and further purification of these mucins by density-gradient ultra-centrifugation in caesium chloride. Agarose gel electrophoresis, Western blotting and amino acid compositional analysis determined the size, purity and identity of the mucins. The inhibitory activity of crude saliva and purified MUC5B and MUC7, from HIV negative (n=20) and HIV positive (n=20) donors, was tested by their incubation with subtype C HIV-1 and subsequent infection of peripheral blood mononuclear cells (PBMCs). PCR was done on tandem repeat regions of MUC5B and MUC7 DNA to investigate whether any association existed between gene polymorphism and susceptibility to infection.

Results

There was an inter-individual variation in the amounts of MUC5B and MUC7 in saliva. In contrast to previous studies, crude saliva and purified mucins from both HIV negative and HIV positive individuals inhibited the infection of HIV-1 in an in vitro assay. DNA analysis of the tandem repeat regions of MUC5B and MUC7 revealed no difference between groups.

Conclusions

Crude saliva and its mucins, MUC5B and MUC7, from both uninfected controls and HIV positive individuals inhibited HIV-1 in an in vitro assay.

【 授权许可】

   
2012 Peacocke et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]: UNAIDS Epidemic Update 2010 GLOBAL REPORT. http://www.unaids.org/globalreport/documents/20101123_GlobalReport_full_en.pdf webcite.
• [2]Habte HH, Mall AS, de Beer C, Lotz ZE, Kahn D: The role of crude human saliva and purified salivary MUC5B and MUC7 mucins in the inhibition of Human Immunodeficiency Virus type 1 in an inhibition assay. Virol J 2006, 3:99. BioMed Central Full Text
• [3]Habte HH, de Beer C, Lotz ZE, Roux P, Mall AS: Anti-HIV-1 activity of salivary MUC5B and MUC7 mucins from HIV patients with different CD4 counts. Virol J 2010, 7:269. BioMed Central Full Text
• [4]Bergey EJ, Cho MI, Blumberg BM, Hammarskjold ML, Rekosh D, Epstein LG, Levine MJ: Interaction of HIV-1 and human salivary mucins. J Acquir Immune Defic Syndr 1994, 7(10):995-1002.
• [5]Baron S, Poast J, Cloyd MW: Why is HIV rarely transmitted by oral secretions? Saliva can disrupt orally shed, infected leukocytes. Arch Intern Med 1999, 159(3):303-310.
• [6]Kazmi SH, Naglik JR, Sweet SP, Evans RW, O’Shea S, Banatvala JE, Challacombe SJ: Comparison of human immunodeficiency virus type 1-specific inhibitory activities in saliva and other human mucosal fluids. Clin Vaccine Immunol 2006, 13(10):1111-1118.
• [7]Phillips J, Qureshi N, Barr C, Henrard DR: Low level of cell-free virus detected at high frequency in saliva from HIV-1-infected individuals. AIDS 1994, 8(7):1011-1012.
• [8]Archibald DW, Cole GA: In vitro inhibition of HIV-1 infectivity by human salivas. AIDS Res Hum Retroviruses 1990, 6(12):1425-1432.
• [9]Wu Z, Van Ryk D, Davis C, Abrams WR, Chaiken I, Magnani J, Malamud D: Salivary agglutinin inhibits HIV type 1 infectivity through interaction with viral glycoprotein 120. AIDS Res Hum Retroviruses 2003, 19(3):201-209.
• [10]Malamud D, Abrams WR, Barber CA, Weissman D, Rehtanz M, Golub E: Antiviral Activities in Human Saliva. Adv Dent Res 2011, 23(1):34-37.
• [11]Mall AS: Analysis of mucins: role in laboratory diagnosis. J Clin Pathol 2008, 61:1018-1024.
• [12]Bafna S, Kaur S, Batra SK: Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells. Oncogene 2010, 29:2893-2904.
• [13]Rousseau K, Vinall LE, Butterworth SL, Hardy RJ, Holloway J, Wadsworth MEJ, Swallow DM: MUC7 Haplotype Analysis: Results from a Longitudinal Birth Cohort Support Protective Effect of the MUC7*5 Allele on Respiratory Function. Ann Hum Genet 2006, 70:417-427.
• [14]Vinall LE, Fowler JC, Jones AL, Kirkbride HJ, de Bolos C, Laine A, Porchet N, Gum JR, Kim YS, Moss FM, Mitchell DM, Swallow DM: Polymorphism of human mucin genes in chest disease: possible significance of MUC2. Am J Respir Cell Mol Biol 2000, 23(5):678-686.
• [15]Kirkbride HJ, Bolscher JG, Nazmi K, Vinall LE, Nash MW, Moss FM, Mitchell DM, Swallow DM: Genetic polymorphism of MUC7: allele frequencies and association with asthma. Eur J Hum Genet 2001, 9(5):347-354.
• [16]Desseyn JL, Rousseau K, Laine A: Fifty-nine bp repeat polymorphism in the uncommon intron 36 of the human mucin gene MUC5B. Electrophoresis 1999, 20(3):493-496.
• [17]Mall AS: Mucus: slippery, sticky, but sweet and satisfying: 29th D. J. du Plessis Lecture, delivered at the Surgical Research Society Meeting, Cape Town, 3 July 2008. S Afr J Surg 2008, 46(4):100-105.
• [18]Nagashunmugam T, Friedman HM, Davis C, Kennedy S, Goldstein LT, Malamud D: Human submandibular saliva specifically inhibits HIV type 1. AIDS Res Hum Retroviruses 1997, 13(5):371-376.
• [19]Devine PL, McKenzie IF: Mucins: structure, function, and associations with malignancy. Bioessays 1992, 14(9):619-625.
• [20]Graham RA, Burchell JM, Taylor-Papadimitriou J: The polymorphic epithelial mucin: potential as an immunogen for a cancer vaccine. Cancer Immunol Immunother 1996, 2:71-80.
• [21]Habte HH: The Inhibition of HIV-1 Activity by Crude Mucus and Purified Mucin (Mucous glycoproteins) from Saliva, Breast milk and the Cervical tract of Normal subjects. HIV positive Individuals and Patients with HIV-AIDS. PhD, University of Cape Town; 2007.
• [22]Habte HH, de Beer C, Lotz ZE, Tyler MG, Kahn D, Mall AS: Inhibition of human immunodeficiency virus type 1 activity by purified human breast milk mucin (MUC1) in an inhibition assay. Neonatology 2008, 93(3):162-170.
• [23]Habte HH, Kotwal GJ, Lotz ZE, Tyler MG, Abrahams M, Rodriques J, Kahn D, Mall AS: Antiviral activity of purified human breast milk mucin. Neonatology 2007, 92(2):96-104.
• [24]Thornton DJ, Khan N, Mehrotra R, Howard M, Veerman E, Packer NH, Sheehan JK: Salivary mucin MG1 is comprised almost entirely of different glycosylated forms of the MUC5B gene product. Glycobiology 1999, 9(3):293-302.
• [25]Mall A, Merrifield E, Fourie J, McLeod H, Hickman R: Alterations in Porcine Gastric Mucin during development of experimental ulceration. Digestion 1997, 58(2):138-146.
• [26]Mall A, McLeod H, Hickman R, Kahn D, Dent DM: Fragmentation pattern of mucins in normal and diseased gastric mucosae: A glycoprotein fractionates with gastric mucins purified from mucosal scrapings of cancer and peptic ulcer patients. Digestion 1999, 60(3):216-226.
• [27]Carlstedt I, Lindgren H, Sheehan JK, Ulmsten U, Wingerup L: Isolation and characterisation of human cervical-mucus glycoproteins. Biochem J 1983, 211:13-22.
• [28]Carlstedt I, Lindgren H, Sheehan JK: The macromolecular structure of human cervical-mucus glycoproteins. Biochem J 1983, 213:427-435.
• [29]Pearson JP, Allen A, Parry S: A 70000-molecular-weight protein isolated from purified pig gastric mucus glycoprotein by reduction of disulphide bridges and its implication in the polymeric structure. Biochem J 1981, 197(1):155-162.
• [30]Thomsson KA, Prakobphol A, Leffler H, Reddy MS, Levine MJ, Fisher SJ, Hansson GC: The salivary mucin MG1 (MUC5B) carries a repertoire of unique oligosaccharides that is large and diverse. Glycobiology 2002, 12(1):1-14.
• [31]Kannan S, Lakku RA, Niranjali D, Jayakumar K, Steven AH, Taralakshmi VV, Chandramohan S, Balakrishnan R, Schmidt C, Halagowder D: Expression of peanut agglutinin-binding mucin-type glycoprotein in human esophageal squamous cell carcinoma as a marker. Mol Cancer 2003, 2:38. BioMed Central Full Text
• [32]Composition of Saliva. www.lfhk.cuni.cz/rezacovam/anglicky/saliva.ppt webcite.
• [33]Allen A, Flemstrom G: Gastroduodenal mucus bicarbonate barrier: protection against acid and pepsin. Am J Physiol Cell Physiol 2005, 288(1):1-19.
• [34]Creeth JM, Denborough MA: The use of equilibrium-density-gradient methods for the preparation and characterization of blood-group-specific glycoproteins. Biochem J 1970, 117(5):879-891.
• [35]Mall AS, Chirwa N, Govender D, Lotz Z, Tyler M, Rodrigues J, Kahn D, Goldberg P: MUC2, MUC5AC and MUC5B in the mucus of a patient with pseudomyxoma peritonei: Biochemical and immunohistochemical study. Pathol Int 2007, 57(8):537-547.
• [36]Mantle M, Allen A: A colorimetric assay for glycoproteins based on the periodic acid/Schiff stain [proceedings]. Biochem Soc Trans 1978, 6(3):607-609.
• [37]Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem 1951, 193(1):265-275.